Home » Stocks » CATB

Catabasis Pharmaceuticals, Inc. (CATB)

Stock Price: $2.88 USD 0.03 (1.05%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $2.82 -0.06 (-2.08%) Feb 26, 7:53 PM
Market Cap 67.44M
Revenue (ttm) n/a
Net Income (ttm) -34.93M
Shares Out 19.42M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $2.88
Previous Close $2.85
Change ($) 0.03
Change (%) 1.05%
Day's Open 2.80
Day's Range 2.73 - 2.95
Day's Volume 632,656
52-Week Range 1.25 - 8.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 4 weeks ago

Catabasis Pharma (CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences and a PIPE. The post CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing To...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.

InvestorPlace - 2 months ago

Catabasis Pharmaceuticals (CATB) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. The post Catabasis Pharmaceuticals: 9 Things for Potential CATB Sto...

GuruFocus - 2 months ago

There are some investors who buy stocks that are trading below their liquidation value because they believe they can make remarkable gains out of their investments after the market has reasses...

Other stocks mentioned: KBSF, NVFY
InvestorPlace - 4 months ago

Catabasis Pharmaceuticals (CATB) news for Tuesday includes incredibly poor results from a clinical trial hammering CATB stock hard. The post Catabasis Pharmaceuticals News: Why CATB Stock Is P...

Seeking Alpha - 4 months ago

Catabasis is approaching its highly anticipated Q4 readout for their Phase III PolarisDMD study. If the data is acceptable, Catabasis expects to file an NDA in 2021.

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.

Zacks Investment Research - 6 months ago

Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Seeking Alpha - 11 months ago

Catabasis: Worth A Look Ahead Of Phase III Data

Seeking Alpha - 11 months ago

Catabasis Pharmaceuticals Inc. (CATB) CEO Jill Milne on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.

Seeking Alpha - 1 year ago

Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q3 2019 Results - Earnings Call Transcript

24/7 Wall Street - 1 year ago

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) has announced that it completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study.

Seeking Alpha - 1 year ago

Catabasis Pharmaceuticals (CATB) CEO, Jill Milne on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Catabasis enrollment is moving fast, having completed enrollment in certain countries, and is on track to report results from the phase 3 PolarisDMD study by second half of 2020.

Seeking Alpha - 1 year ago

Catabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q4 2018 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Catabasis (CATB) beats earnings estimates in the fourth quarter of 2018. The company has no revenues. Shares up.

About CATB

Catabasis Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research coll... [Read more...]

Industry
Biotechnology
IPO Date
Jun 25, 2015
CEO
Jill C. Milne
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
CATB
Full Company Profile

Financial Performance

Financial Statements